Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p186
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 186/312)
Character Range: 16629016–16636555

for this patient; AND
                                                    Brimonidine with timolol                                               The condition must have been inadequately controlled with monotherapy; AND
                                                                                                                           Patient must have open-angle glaucoma; OR
                                                    Brinzolamide with brimonidine                                          Patient must have ocular hypertension.

                                                    Brinzolamide with timolol

                                                    Dorzolamide with timolol

                                                    Latanoprost with timolol

                                                    Travoprost with timolol

C15559              P15559         CN15559          Carbomer                                                               Severe dry eye syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 15559
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                    Carmellose                                                             Patient must be sensitive to preservatives in multi-dose eye drops.

                                                    Hyaluronic acid

                                                    Hypromellose

                                                    Paraffin

                                                    Perfluorohexyloctane

                                                    Polyethylene glycol 400 with propylene glycol

                                                    Soy lecithin

C15560              P15560         CN15560          Carbomer                                                               Severe dry eye syndrome

                                                    Hypromellose

                                                    Hypromellose with dextran

                                                    Polyethylene glycol 400 with propylene glycol

C15564              P15564         CN15564          Levodopa with carbidopa and entacapone                                 Parkinson disease
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must be being treated with levodopa decarboxylase inhibitor combinations; AND
                                                                                                                           Patient must be experiencing fluctuations in motor function due to end-of-dose effect.
C15565              P15565         CN15565          Levodopa with carbidopa and entacapone                                 Parkinson disease
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must be stabilised on concomitant treatment with levodopa decarboxylase inhibitor combinations and entacapone.
C15566              P15566         CN15566          Tiotropium                                                             Severe asthma
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must have experienced at least one severe asthma exacerbation in the 12 months prior to having first commenced treatment for severe asthma, which required systemic corticosteroid treatment despite each of: (i) receiving optimised asthma therapy, (ii) being assessed for adherence to therapy, (iii) being assessed for correct inhaler technique; AND
                                                                                                                           The treatment must be used in combination with a maintenance combination of an inhaled corticosteroid (ICS) and a long acting beta-2 agonist (LABA) unless a LABA is contraindicated.
                                                                                                                           Patient must be at least 18 years of age.
                                                                                                                           Optimised asthma therapy includes adherence to the maintenance combination of an inhaled corticosteroid (at least 800 micrograms budesonide per day or equivalent) and a long acting beta-2 agonist.
C15568              P15568         CN15568          Pramipexole                                                            Parkinson disease
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C15570              P15570         CN15570          Pramipexole                                                            Parkinson disease
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C15572              P15572         CN15572          Bisacodyl                                                              Terminal malignant neoplasia
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for